131I-B72.3

131I-B72.3 is a radiolabeled chimeric monoclonal antibody designed for the targeted detection and treatment of certain cancers, notably metastatic colorectal and ovarian cancer. The antibody component, B72.3, specifically binds to the tumor-associated glycoprotein 72 antigen (TAG-72), which is commonly overexpressed on many adenocarcinomas. The humanized chimeric antibody, constructed from murine V-regions and human IgG4 constant regions, is chemically conjugated with the radioisotope iodine-131. Its mechanism involves binding to TAG-72 on cancer cells, thereby allowing for both imaging and localized radiation delivery to tumor tissue. Its primary mechanism of action is radioimmunotherapy, providing targeted cytotoxic radiation via the isotope while minimizing exposure to normal tissues[1][2][3][5]. The drug was developed for diagnostic and therapeutic (radioimmunotherapy) use and was tested primarily in clinical trials for metastatic colorectal cancer and for detection/localization of ovarian and other TAG-72 expressing malignancies.

Other names

iodine-131-B72.3iodine131-B72.3iodine 131-B72.3131I-chimeric B72.3I-131 B72.3I131 B72.3I 131 B72.3